India -
engelsk -
Central Drugs Standard Control Organization
botroclot 10ml f. topical sol
juggat - haemocoagulase - f. topical sol - (isolated from bothrops atrox or jararaca) - 10ml
India -
engelsk -
Central Drugs Standard Control Organization
botroclot 10ml sol
juggat - haemocoagulase - sol - (isolated from bothrops atrox or bothrox jararaca) - 10ml
India -
engelsk -
Central Drugs Standard Control Organization
botropase 1/2;ml inj
juggat - haemocoagulase - inj - 1cu/ml(botropase) - 1/2;ml
India -
engelsk -
Central Drugs Standard Control Organization
colase 3x1 ml inj
samarth - haemocoagulase - inj - 1 cu/ml - 3x1 ml
India -
engelsk -
Central Drugs Standard Control Organization
reptilase 1ml inj
troikaa - haemocoagulase - inj - 1u. - 1ml
Malaysia -
malayisk -
NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
transamin capsule 250mg
Australia -
engelsk -
Department of Health (Therapeutic Goods Administration)
bortezomib ever pharma bortezomib 3.5 mg/1.4 ml solution for injection vial
interpharma pty ltd - bortezomib, quantity: 3.5 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections; mannitol - bortezomib ever pharma, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. bortezomib ever pharma, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib ever pharma is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. bortezomib ever pharma in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.
Australia -
engelsk -
Department of Health (Therapeutic Goods Administration)
bortezomib ever pharma bortezomib 2.5 mg/1 ml solution for injection vial
interpharma pty ltd - bortezomib, quantity: 2.5 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections; mannitol - bortezomib ever pharma, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. bortezomib ever pharma, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib ever pharma is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. bortezomib ever pharma in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.